Marché des aliments médicaux pour les erreurs innées du métabolisme en Asie-Pacifique – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché des aliments médicaux pour les erreurs innées du métabolisme en Asie-Pacifique

La consommation de compléments alimentaires et d'aliments médicaux recommandés augmente par rapport aux médicaments à base d'enzymes. La tendance à s'éloigner des médicaments au profit des compléments alimentaires et des aliments médicaux devrait changer en raison de l'augmentation des coûts des soins de santé et de la préférence des clients pour des solutions de gestion des maladies rapides et faciles. La demande d'aliments médicaux a augmenté par rapport à l'année précédente en raison de l'augmentation des dépenses en aliments médicaux et de l'introduction de nouveaux produits pour de nouvelles indications.

Français Data Bridge Market Research analyse que la valeur du marché des aliments médicaux pour les erreurs innées du métabolisme est de 531,59 millions USD en 2022, et devrait atteindre 1 354,28 millions USD d'ici 2030, à un TCAC de 12,4 % au cours de la période de prévision 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur du marché, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des aliments médicaux pour les erreurs innées du métabolisme en Asie-Pacifique  

Market Definition

The term "medical food" was coined by the Orphan Drug Act, which was amended in 1988, and directed the FDA to develop regulations allowing such specialised food formulations to be used under medical supervision for the nutritional management of a disease or condition with medically established distinctive nutritional requirements. Some diseases known as inborn metabolic abnormalities which occurs when the body is unable to turn food into energy. Gene mutations result in decreased or absent synthesis of a certain enzyme that breaks down specific compounds. There are significant difficulties, because of the accumulation of harmful compounds. They are given particular diets, often known as medicinal meals, under the supervision of doctors in order to address these conditions.

Asia-Pacific Medical Foods for Inborn Errors of Metabolism Market Dynamics

Drivers

• Surge in preference for dietary supplements

Contrary to enzyme-based therapeutic drugs, nutritional supplements and foods that have been prescribed for medical purposes are growing in popularity. Rising healthcare expenses and consumer preference for rapid, low-cost and effective disease treatment approaches are most likely to blame for the trend away from pharmaceuticals and toward dietary supplements and therapeutic foods. The term "medical food" refers to a class of products that are used in the nutritional management of a number of disorders including inborn metabolic abnormalities, and that include certain nutrients to match the nutrient requirements of patients with particular illnesses. These specific factors are drive the market's expansion.

Opportunities

• Rising use of medical foods

The market is regulated by authoritative and medical foods are employed as therapy choices for inborn metabolic abnormalities. Between 85% and 90% of a person's dietary requirements are satisfied by the nutritional therapy for congenital metabolic abnormalities. These supplements are also almost completely side effect-free, making them safe for people of all ages. Private medical insurance in the US and a few other nations have recently started to provide reimbursement programmes for the use of specific medical meals. As a result, market expansion during the forecast period is anticipated to be driven by increased usage of medical food and nutrient supplements.

Restraints/Challenges

• High cost of medical foods

Medical foods are created for people who have difficulty swallowing, digesting, absorbing or metabolising regular foods or nutrients and whose nutritional management cannot be accomplished solely by altering their regular diet. Many health insurance policies in the U.S. do not adequately cover medical foods and without insurance many families cannot afford their high cost.

This medical foods for inborn errors of metabolism market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the medical foods for inborn errors of metabolism market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent developments

• In 2019, In the Netherlands, Nutricia established a sustainable facility. The large investment in the Nutricia Cuijk facility raised the production of specialized infant formula and the market's income.
• In 2022, Mead Johnson & Company, LLC announced that it had merged entirely with Reckitt Benckiser Group plc (RB). It was anticipated that the Mead Johnson brand and business would continue to grow to the effective innovation and marketing practices used by Reckitt Benckiser plc businesses.

Asia-Pacific Medical Foods for Inborn Errors of Metabolism Market Scope

The medical foods for inborn errors of metabolism market is segmented on the basis of products, age group, diseases, forms, packaging and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products

• Amino Acid
• Glytactin with GMP Amino Acid-Modified Infant Formula with Iron
• Low-Calcium/Vitamin D-Free Infant Formula with Iron
• Low Protein Food
• Others

 Age Group

• Infants
• Weaning
• Adolescent
• Adults

 Diseases

• Phenylketonuria (PKU)
• Maple Syrup Urine Disease (MSUD)
• Homocystinuria
• Methylmalonic Acidemia
• Organic Acidurias
• Propionic Acidemia
• Isovaleric Acidemia
• Disorders of Leucine Metabolism
• Glutaric Acidemia Type I Renal Disease
• Tyrosinemia Types I and II
• Urea Cycle Disorders
• Others

 Forms

• Powder
• Liquids
• Gels
• Others

 Packaging

• Can
• Jar
• Packets
• Bottle
• Others

Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Drugs Stores
• Online Pharmacies
• Others

Medical Foods for Inborn Errors of Metabolism Market Regional Analysis/Insights

The medical foods for inborn errors of metabolism market is analyzed and market size insights and trends are provided by country, products, age group, diseases, forms, packaging and distribution channel as referenced above.

The countries covered in the medical foods for inborn errors of metabolism market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).

Germany is dominating the medical foods for inborn errors of metabolism market due to the increase in the number of new-born screening procedures and a rise in the number of medical food recommendations from doctors.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

Le marché des aliments médicaux pour les erreurs innées du métabolisme vous fournit également une analyse détaillée du marché pour chaque pays, la croissance des dépenses de santé pour les biens d'équipement, la base installée de différents types de produits pour le marché des aliments médicaux pour les erreurs innées du métabolisme, l'impact de la technologie utilisant les courbes de vie et les changements dans les scénarios réglementaires des soins de santé et leur impact sur le marché des aliments médicaux pour les erreurs innées du métabolisme. Les données sont disponibles pour la période historique 2011-2021.

Analyse du paysage concurrentiel et des parts de marché des aliments médicaux pour les erreurs innées du métabolisme

Le paysage concurrentiel du marché des aliments médicaux pour les erreurs innées du métabolisme fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Asie-Pacifique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination de l'application. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liées au marché des aliments médicaux pour les erreurs innées du métabolisme.

Certains des principaux acteurs opérant sur le marché des aliments médicaux pour les erreurs innées du métabolisme sont :

• Nestlé Health Science (Suisse)
• Nutricia (Pays-Bas)
• Solace Nutrition (États-Unis)
• Abbott (États-Unis)
• Mead Johnson & Company, LLC. (États-Unis)
• BioMarin Pharmaceutical (États-Unis)
• Ajinomoto Cambrooke, Inc. (États-Unis)
• Poa Pharma (Suède)
• PKU-MDmil (États-Unis)
• Dr.Schar AG/SPA Primus Pharmaceuticals, Inc. (Italie)
• Pristine Organics Pvt. Ltd. (Inde)
• TAEG (États-Unis)
• Aliments Ener-G (États-Unis)
• Promin Metabolics (Royaume-Uni) 

SKU-53801